Pharmacovigilance data quality is essential to understanding the safety of medicines and supporting reliable safety decisions. Yet an error rarely remains confined to the record in which it first occurs. An incorrect product identifier, an incomplete event description or a missed follow-up can pass through multiple systems and processes before the underlying issue is identified.
By then, the error may affect case reconciliation, medical review, regulatory reporting or the interpretation of safety information. Individual processing steps may appear complete, while the information carried forward remains inaccurate or unreliable.
For Marketing Authorisation Holders (MAHs), this highlights a critical distinction: processing a safety report correctly does not necessarily mean maintaining data quality throughout its lifecycle. Effective pharmacovigilance data quality management requires MAHs to identify where errors originate, understand how they move across systems and organisational handoffs, and establish controls that prevent downstream consequences.
Why Pharmacovigilance Data Quality is Becoming a Strategic Issue
The reliability of safety information depends on more than the accuracy of the final Individual Case Safety Report (ICSR). It also depends on whether information retains its meaning as it moves from the original source through intake, assessment, database entry, reconciliation and regulatory transmission.
Three related concepts are particularly important:
- Data accuracy: Whether recorded information correctly represents the available source information.
- Data completeness and consistency: Whether relevant information is present and related records agree where they should.
- Data integrity: Whether information remains reliable and traceable throughout its lifecycle, with appropriate controls over access and changes.
These dimensions are related but not interchangeable. A complete record can contain an incorrect product identifier, and a technically valid electronic message can still carry inaccurate clinical information. For MAHs, the priority is to understand where errors enter, which controls should detect them and whether corrective actions prevent recurrence. This makes drug safety data quality an ongoing operational responsibility rather than a final review activity.
Where Do Safety Data Errors Begin?
Safety-data errors can originate at any stage of the pharmacovigilance lifecycle. The point where an error is discovered may be different from where it began.
- Source Collection and Initial Intake
Reporting sources may provide incomplete information, informal product names or unclear event descriptions. Errors in initial recording, such as incorrect identifiers or receipt dates, can enter the case record if not detected promptly. - Data Transfer and Interpretation
Transferring information between forms, emails, partner databases and safety systems can introduce transcription or mapping errors, potentially changing product identifiers or losing important details. - Case Processing and Medical Review
Reviewers may confirm that required fields are complete without checking them against the source, allowing inaccurate information to persist in the processed case. - Reconciliation and Reporting
Comparisons with other records or electronic submissions may reveal discrepancies. However, errors can remain undetected when the same incorrect information appears consistently across connected systems.
The Most Common Data-Quality Problems in Pharmacovigilance
Individual defects can become more consequential when they affect subsequent processing or remain undetected across systems. Effective ICSR data quality controls should address both the error and the conditions that allow it to persist.
| Data-Quality Issue | How It Propagates | Key Control |
|---|---|---|
| Incorrect product identifier | Wrong product association | Verify against source and product data |
| Incomplete event description | Loss of clinical context | Check fields against the source narrative |
| Incorrect dates | Affects chronology or reporting timelines | Validate dates against source records |
| Inconsistent coding | Complicates searches and analysis | Use controlled terminology and coding review |
| Duplicate records | Duplicated or fragmented information | Apply duplicate-detection and case-linking rules |
| Unlinked follow-up | Important details may be missed | Verify case matching and track follow-up |
| Conflicting system data | Different versions of a record | Reconcile systems and resolve discrepancies |
| Transmission errors | Submission rejection or delay | Validate messages against applicable requirements |
These issues do not all carry the same risk. Some may affect clinical interpretation, while others may affect traceability, reporting or electronic transmission. MAHs should assess discrepancies according to their nature, potential impact and applicable requirements, document their resolution and escalate material issues appropriately.
Why Clinical and Safety Data Silos Create Hidden PV Risk
Safety information may be distributed across clinical operations, medical information, product quality, patient support programmes and commercial affiliates. Each function may maintain records relevant to the same product, event or patient. The risk arises when these records are not reliably connected. A product complaint containing safety information may not be linked to the relevant ICSR, or an updated record in one system may not be reflected in another.
MAHs can reduce this risk through five practical controls:
- Common reference rules: Define how case, product and event identifiers are used across relevant systems.
- Clear data ownership: Assign responsibility for creating, updating and correcting information.
- Risk-based reconciliation: Compare relevant records using appropriate matching criteria.
- Exception management: Assign owners and timelines to discrepancies and document their resolution.
- Change impact assessment: Review whether system upgrades, interface changes or revised data definitions affect existing data links.
How Global Affiliates, Vendors and Partners Affect Safety Data Quality
Global pharmacovigilance operations introduce additional handoffs. Affiliates, distributors, licensing partners and service providers may receive, process, translate, transfer or update safety information before it reaches the central MAH system. If responsibilities are unclear, an error can fall between organisational boundaries. One party may assume that the information has been verified, while the receiving party may assume that verification was already completed.
A strong oversight model should address four areas:
- Transfer Specifications and Acceptance Criteria
Define required data, formats, timelines, reconciliation expectations and procedures for rejected transfers. Successful transfer does not guarantee data accuracy. - Ownership of Discrepancies
Assign responsibility for investigating errors, approving corrections, notifying partners and assessing downstream impact. - Performance Monitoring
Track recurring errors, unresolved discrepancies, transfer delays and rejected messages to identify trends and potential root causes. - Corrective Action and Effectiveness
Address root causes through corrective and preventive actions (CAPAs), then verify that the controls introduced reduce recurrence.
Where applicable under the EU framework, the Qualified Person Responsible for Pharmacovigilance (QPPV) requires appropriate oversight of the pharmacovigilance system and access to relevant safety information. Effective QPPV data quality oversight includes visibility into material weaknesses and their remediation, not just isolated case defects. Outsourcing may change who performs a task, but it does not remove the MAH’s applicable regulatory responsibilities.
What ICH E2D(R1), E2B(R3) and EMA/FDA Data Initiatives Mean for MAHs
Regulatory developments affect the types of safety information organisations collect and how that information is documented and transmitted. MAHs should assess how each applicable change affects their data flows, procedures, systems and reporting obligations.
- ICH E2D(R1): Changes to Post-Approval Safety-Data Management
ICH E2D(R1) updates the framework for managing and reporting post-approval safety information, including information from sources such as patient support programmes, market research programmes and other organised data collection systems.
In the EU, the guideline became effective on 18 March 2026, with a transition period ending on 18 September 2026. As of October 2026, MAHs operating under the EU framework should have addressed the applicable implementation requirements. The EMA implementation strategy explains the regional approach and should be read alongside relevant EU requirements. - ICH E2B(R3): Standardised Electronic ICSR Exchange
ICH E2B(R3) defines the data elements and message structure used for electronic ICSR exchange. Standardised transmission supports consistent data exchange, but technical compliance does not guarantee clinical accuracy.
In the EU, EudraVigilance uses the applicable ISO ICSR/ICH E2B(R3) format and associated standards. In the US FDA provides E2B(R3) implementation guidance and regional data requirements for submissions to its Adverse Event Monitoring System (AEMS). For MAHs, this means an electronic interface can transmit a message successfully while carrying an incorrect value from the originating database. Validation should therefore address both message compliance and the accuracy of the underlying information. - EMA and FDA: Practical Implications for Data Controls
EMA resources describe applicable reporting standards, terminology and implementation expectations for EudraVigilance. FDA provides technical specifications and regional data requirements for electronic ICSR submissions to AEMS.
From 1 October 2026, applicable postmarketing ICSRs for human drug products, biological products and relevant combination products submitted through FDA’s Electronic Submissions Gateway Next Generation (ESG NextGen) must use E2B(R3) data standards. The Safety Reporting Portal has separate submission arrangements, so MAHs should confirm the requirements for their specific reporting pathway.
How MAHs Can Build an End-to-End PV Data Quality Framework
An effective framework connects identified risks with appropriate controls, accountable owners and measurable outcomes. The following steps provide a practical starting point.
- Map Data Flow: Identify key sources, handoffs and risk points.
- Prioritise Critical Data: Focus on fields affecting case validity, safety assessment and reporting.
- Prevent Errors: Apply source verification, validation and mapping checks.
- Verify Handoffs: Compare transferred data and investigate discrepancies.
- Assign Ownership: Define responsibility and timelines for resolving errors.
- Maintain Traceability: Keep audit trails and documented correction records.
- Monitor Quality: Track recurring errors and investigate trends.
- Verify CAPAs: Confirm corrective actions reduce recurrence.
- Review After Changes: Reassess controls following regulatory, system or vendor changes.
Quality indicators should have defined calculation methods, data sources, owners, review frequencies and escalation thresholds. An increase in errors may signal a local processing problem, a system-interface defect or a change in incoming data. The metric should trigger investigation rather than be treated as proof of a specific root cause. Similarly, CAPA effectiveness should be assessed through evidence that the original failure mode has been controlled, not simply through completion of training or revision of a procedure.
The PV Data Quality Control Chain
The PV Data Quality Control Chain provides a practical way to connect individual controls across the safety-data lifecycle:
Capture → Verify → Process → Compare → Reconcile → Correct → Assess Impact → Prevent Recurrence
- Capture: Preserve the information as received, including relevant source details and dates.
- Verify: Check critical information against the source and identify missing context.
- Process: Apply controlled data-entry, coding and review procedures.
- Compare: Check whether structured fields, narratives and related records agree.
- Reconcile: Investigate discrepancies across systems, affiliates and partners.
- Correct: Amend affected records through authorised procedures while preserving traceability.
- Assess impact: Determine whether the error affected reporting, downstream records, analyses or previous decisions.
- Prevent recurrence: Address the root cause and verify that corrective actions are effective.
How DDReg Supports Pharmacovigilance Data Quality
DDReg’s pharmacovigilance support can contribute to reliable safety-data management through activities such as ICSR processing, quality review, literature monitoring services, aggregate reporting services and related PV services, depending on the agreed scope of engagement.
Relevant support may include:
- Case-level quality review: Identifying inconsistencies in case information, coding, narratives and supporting documentation.
- Processing and reconciliation support: Helping identify discrepancies and route them for documented resolution.
- Regulatory reporting support: Supporting report preparation and review against applicable requirements.
- Quality-process improvement: Helping assess recurring issues, clarify responsibilities and strengthen documented controls.
The appropriate approach depends on the MAH’s existing PV system, data flows, markets and identified risks. These activities should operate within the MAH’s governance arrangements and agreed responsibilities.
Explore DDReg’s pharmacovigilance services to learn more.
Conclusion
Pharmacovigilance data quality depends on how reliably safety information is captured, transferred, reviewed and maintained across the product lifecycle. Errors become more difficult to control when they pass through multiple systems without independent verification or clear ownership.
For MAHs, the priority is to connect preventive controls with timely detection, documented resolution and assessment of downstream impact. The PV Data Quality Control Chain offers a practical way to organise these activities, helping teams address not only individual errors but also the process weaknesses that allow them to recur. By embedding these controls into routine pharmacovigilance operations, organisations can strengthen data reliability, improve traceability and support more dependable safety assessments and regulatory decisions.
Frequently Asked Questions
Pharmacovigilance data quality concerns the accuracy, completeness, consistency and reliability of safety information throughout its lifecycle, from initial receipt to processing, reporting and downstream use.
Depending on the error, incorrect or incomplete information may affect product attribution, reconciliation, medical interpretation, regulatory reporting or downstream analysis. The impact should be assessed based on the specific information involved.
Data quality concerns whether information is accurate, complete and fit for its intended use. Data integrity concerns whether information remains reliable and traceable throughout its lifecycle, including through appropriate access controls and documented changes.
The QPPV has defined responsibilities within the EU pharmacovigilance system. Access to relevant safety information and visibility into significant quality or compliance issues support effective oversight, alongside clearly assigned operational responsibilities.